Javascript must be enabled to continue!
Clinical Outcomes with Unfractionated Heparin or Low-Molecular-Weight Heparin as Bridging Therapy in Patients on Long-Term Oral Anticoagulants: Results from the REGIMEN Registry.
View through CrossRef
Abstract
Introduction: The optimal perioperative management of patients on long-term oral anticoagulant (OAC) therapy is currently unclear. There have been no large prospective clinical studies comparing unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) as bridge therapy in this setting. This registry compared the efficacy and safety of in-hospital UFH with mostly outpatient-based LMWH for perioperative bridging in patients on long-term OAC.
Methods: REGIMEN is a large, prospective, multi-center registry in the USA and Canada of patients receiving chronic anticoagulation and requiring a perioperative bridge for an elective procedure or surgery. Patients who were ≥18 years, on OAC ≥3 months prior to the elective procedure, and who had heparin as a bridge to OAC for ≥2 days in the pre- and/or post-operative period, were included in the registry. Data on patient characteristics and primary clinical adverse events up to 30 days post-procedure were collected and compared between UFH and LMWH.
Results: Of 1077 patients enrolled in this registry, 180 received UFH alone and 721 received LMWH (treatment or prophylactic dose) alone. Patients not receiving the same heparin pre- and post-procedure (n=123) and those undergoing multiple procedures (n=53) were excluded from the analysis. Patients on LMWH spent less time in hospital and were less likely to undergo major surgery or receive general anesthesia. Adverse events occurred at similar rates in both groups (table 1), and were primarily minor bleeds. Univariate analysis for procedure variables showed that UFH versus LMWH, intra-procedural anticoagulants/thrombolytics, procedure duration ≥45 minutes and general anesthesia were associated with an increased risk of a major adverse event. Logistic regression analysis for major bleeding can be seen in table 2.
Conclusions: REGIMEN, a large, prospective, multi-center registry of patients in the US and Canada requiring bridging therapy with heparin for elective surgery, reveals that bridging therapy with LMWH in selected outpatients is at least as safe and effective as in-hospital UFH.
Table 1. Adverse events in bridged patients
UFH (n=164) LMWH (n=668) p-value Adverse event 28 (17.1%) 108 (16.2%) 0.81 Arterial/venous complication, major bleed, or death 13 (7.9%) 28 (4.2%) 0.07 Adverse Events: Arterial complications: Cardiac valvular or mural thrombus 1 (0.6%) 0 (0%) Intracranial event 1 (0.6%) 2 (0.3%) TIA 1 (0.6%) 2 (0.3%) Peripheral arterial event 1 (0.6%) 0 (0%) Venous complications: DVT 0 (0%) 2 (0.3%) PE 0 (0%) 0 (0%) Major bleed 9 (5.5%) 22 (3.3%) 0.25 Minor bleed 15 (9.1%) 80 (12.0%) 0.34 Thrombocytopenia 2 (1.2%) 3 (0.4%) Death 2 (1.2%) 4 (0.6%)
Table 2. Logistic regression analysis for major bleed
Independent variable Reference OR 95% CI Vascular surgery Not vascular surgery 4.72 0.92–24.09 General surgery Not general surgery 2.25 0.78–6.53 Charlson score >1 Charlson score ≤1 2.24 1.02–4.93 Procedure duration ≥45mins Procedure duration <45mins 1.37 0.59–3.18 LMWH post-op UFH post-op 0.76 0.32–1.81
American Society of Hematology
Title: Clinical Outcomes with Unfractionated Heparin or Low-Molecular-Weight Heparin as Bridging Therapy in Patients on Long-Term Oral Anticoagulants: Results from the REGIMEN Registry.
Description:
Abstract
Introduction: The optimal perioperative management of patients on long-term oral anticoagulant (OAC) therapy is currently unclear.
There have been no large prospective clinical studies comparing unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) as bridge therapy in this setting.
This registry compared the efficacy and safety of in-hospital UFH with mostly outpatient-based LMWH for perioperative bridging in patients on long-term OAC.
Methods: REGIMEN is a large, prospective, multi-center registry in the USA and Canada of patients receiving chronic anticoagulation and requiring a perioperative bridge for an elective procedure or surgery.
Patients who were ≥18 years, on OAC ≥3 months prior to the elective procedure, and who had heparin as a bridge to OAC for ≥2 days in the pre- and/or post-operative period, were included in the registry.
Data on patient characteristics and primary clinical adverse events up to 30 days post-procedure were collected and compared between UFH and LMWH.
Results: Of 1077 patients enrolled in this registry, 180 received UFH alone and 721 received LMWH (treatment or prophylactic dose) alone.
Patients not receiving the same heparin pre- and post-procedure (n=123) and those undergoing multiple procedures (n=53) were excluded from the analysis.
Patients on LMWH spent less time in hospital and were less likely to undergo major surgery or receive general anesthesia.
Adverse events occurred at similar rates in both groups (table 1), and were primarily minor bleeds.
Univariate analysis for procedure variables showed that UFH versus LMWH, intra-procedural anticoagulants/thrombolytics, procedure duration ≥45 minutes and general anesthesia were associated with an increased risk of a major adverse event.
Logistic regression analysis for major bleeding can be seen in table 2.
Conclusions: REGIMEN, a large, prospective, multi-center registry of patients in the US and Canada requiring bridging therapy with heparin for elective surgery, reveals that bridging therapy with LMWH in selected outpatients is at least as safe and effective as in-hospital UFH.
Table 1.
Adverse events in bridged patients
UFH (n=164) LMWH (n=668) p-value Adverse event 28 (17.
1%) 108 (16.
2%) 0.
81 Arterial/venous complication, major bleed, or death 13 (7.
9%) 28 (4.
2%) 0.
07 Adverse Events: Arterial complications: Cardiac valvular or mural thrombus 1 (0.
6%) 0 (0%) Intracranial event 1 (0.
6%) 2 (0.
3%) TIA 1 (0.
6%) 2 (0.
3%) Peripheral arterial event 1 (0.
6%) 0 (0%) Venous complications: DVT 0 (0%) 2 (0.
3%) PE 0 (0%) 0 (0%) Major bleed 9 (5.
5%) 22 (3.
3%) 0.
25 Minor bleed 15 (9.
1%) 80 (12.
0%) 0.
34 Thrombocytopenia 2 (1.
2%) 3 (0.
4%) Death 2 (1.
2%) 4 (0.
6%)
Table 2.
Logistic regression analysis for major bleed
Independent variable Reference OR 95% CI Vascular surgery Not vascular surgery 4.
72 0.
92–24.
09 General surgery Not general surgery 2.
25 0.
78–6.
53 Charlson score >1 Charlson score ≤1 2.
24 1.
02–4.
93 Procedure duration ≥45mins Procedure duration <45mins 1.
37 0.
59–3.
18 LMWH post-op UFH post-op 0.
76 0.
32–1.
81.
Related Results
Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Abstract
Introduction
Among the most frequently used anticoagulants in hematological testing are tetra-acetic acid (EDTA), sodium citrate, and sodium heparin. However, there is a n...
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
BackgroundA clinical dilemma exists in patients with CKD, ESKD, and after kidney transplantation, as they face concurrent risks of both thromboembolic and hemorrhagic complications...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
HEPARIN STIMULATES FIBROBLAST GROWTH INDUCED BY PDGF
HEPARIN STIMULATES FIBROBLAST GROWTH INDUCED BY PDGF
Heparin binds to smooth muscle cells and endothelial cells. It inhibits the proliferation of the smooth muscle cells and modulates the growth of endothelial cells. Fibroblasts whic...
Exploring the Efficacy of Once and Twice Weekly Thyroxine Dosing: A Promising Approach for Hypothyroidism Management
Exploring the Efficacy of Once and Twice Weekly Thyroxine Dosing: A Promising Approach for Hypothyroidism Management
Abstract
Introduction
Hypothyroidism is a common endocrine disorder, in which the management involves daily intake of thyroxine. However, adherence to a daily medication regimen po...
Novel ELISA-Based Assay for Detection of Complement Activation By PF4/Heparin Complexes
Novel ELISA-Based Assay for Detection of Complement Activation By PF4/Heparin Complexes
Abstract
The immune response to platelet factor 4 (PF4)/heparin complexes is a frequent iatrogenic complication of heparin therapy associated with development of hep...
Case Report: Maggots' Infestation As a Predisposing Condition for Heparin-Induced Thrombocytopenia, a Newest Entity
Case Report: Maggots' Infestation As a Predisposing Condition for Heparin-Induced Thrombocytopenia, a Newest Entity
Abstract
Introduction
Thromobocytopenia is a well-recognized complication of heparin with risk of venous or arterial thrombosis. Heparin induced throm...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...

